An observational study in Vulvar Cancer and Quality of Life, sponsored by Karolinska University Hospital. Active, not recruiting at 4 sites in Sweden. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-01.
Sponsored by Karolinska University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this prospective, longitudinal Swedish multi-center study is to assess the quality of life, treatment-related morbidity, unmet needs and satisfaction with care after treatment for vulvar cancer, evaluated by a validated questionnaire.
PRIMARY OBJECTIVES:
Information about:
OUTLINE:
The study is planned as a prospective, longitudinal multi-centre study in Sweden. Since 2017, the treatment of vulvar cancer patients has been accredited to four tertiary referral university hospitals in Sweden; the Sahlgrenska University hospital in Gothenburg, the Linköping University hospital, the Skåne University hospital in Lund and the Karolinska University hospital in Stockholm.
150 patients are estimated for inclusion during a time frame of about 18 months.
Eligible patients will be asked to complete a validated questionnaire at different points of time (before and after treatment). Calculating a response rate of about 50% - 60%, this will result in at least 80 completed questionnaires.
The questionnaires consist of the following parts:
RESULTS:
Results are expected to be available in 2021.
236 studies on the registry are indexed under Vulvar Neoplasms; 69 are open to participants now.
This study's enrollment of 153 is close to the median of 152 across 58 observational studies indexed under Vulvar Neoplasms.
Browse Vulvar Neoplasms studies →Karolinska University Hospital is the lead sponsor of 279 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Women with newly diagnosed invasive vulvar cancer in Sweden during the study time frame.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Whole cohort administration of questionnaire at 7 times
Behavioral: Questionnaire administration
Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
Global quality of life
Measured by the European Organisation of Research and Treatment of Cancer (EORTC)-QLQ-C30-questionnaire. Measurement on a scale between 0-and 100. Higher values represent better quality of life. A change of at least 5-8 points is regarded as clinically significant.
Time frame: 1 year after end of treatment
Vulvar-cancer-specific quality of life
Measured by the EORTC-QLQ-VU34-questionnaire. Higher values represent higher quality of life.
Time frame: 1 year after end of treatment
Satisfaction with Care
Measured by EORTC-PATSAT-questionnaire. Higher score represent higher satisfaction with care.
Time frame: 3--4 months after end of treatment
Depression and anxiety
Measured by the Hospital Anxiety and Depression Index (HADS)-questionnaire. Higher scores represent more depression and anxiety
Time frame: 1 year after end of treatment.
Unmet needs
Measured by the Supportive Care Needs Survey-Short Form (SCNS-SF)-34-questionnaire. Higher scores represent higher needs.
Time frame: 3-4 months after end of treatment.
Started Aug 2019 (actual). Primary completion is estimated for Feb 2027, 90 months after the start.
Of 32 observational studies under Vulvar Neoplasms, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 41. This study's planned 90 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karolinska University Hospital →